Cargando…

Economic burden for Alzheimer’s disease in China from 2010 to 2050: a modelling study

Objectives: We aimed to conduct a modelling study to estimate and predict the economic burden of AD to support the healthcare management of AD in China. Methods: The economic burden of AD was estimated with an evaluation of the prevalence of AD patients and a simulation of annual resource use and co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Clay, Emilie, Zhou, Junwen, Yi, Zhan-Miao, Zhai, Suodi, Toumi, Mondher
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Routledge 2019
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764338/ https://www.ncbi.nlm.nih.gov/pubmed/31595183 http://dx.doi.org/10.1080/20016689.2019.1667195

Ejemplares similares

Projections of the economic burden of care for individuals with dementia in mainland China from 2010 to 2050
por: Huang, Yixiang, et al.
Publicado: (2022)

Projected burden of stroke in China through 2050
por: Yao, Minghong, et al.
Publicado: (2023)

Current and future economic burden of diabetes among working-age adults in Asia: conservative estimates for Singapore from 2010-2050
por: Png, May Ee, et al.
Publicado: (2016)

Erratum to: ‘Current and future economic burden of diabetes among working-age adults in Asia: conservative estimates for Singapore from 2010-2050’
por: Png, May Ee, et al.
Publicado: (2016)

Systematic review of pharmacoeconomic models for schizophrenia
por: Zhou, Junwen, et al.
Publicado: (2018)

Estimation of waste outflows for multiple product types in China from 2010–2050
por: Zeng, Xianlai, et al.
Publicado: (2021)

Global and regional projections of the economic burden of Alzheimer's disease and related dementias from 2019 to 2050: A value of statistical life approach
por: Nandi, Arindam, et al.
Publicado: (2022)

Global Burden of Sickle Cell Anaemia in Children under Five, 2010–2050: Modelling Based on Demographics, Excess Mortality, and Interventions
por: Piel, Frédéric B., et al.
Publicado: (2013)

Contribution of prolonged-release melatonin and anti-benzodiazepine campaigns to the reduction of benzodiazepine and z-drugs consumption in nine European countries
por: Clay, Emilie, et al.
Publicado: (2012)

Global burden and drivers of hyperglycemia: Estimates and predictions from 1990 to 2050
por: Qiu, Hui-Ling, et al.
Publicado: (2023)

Allocating treatment resources for hepatitis C in the UK: a constrained optimization modelling approach
por: Han, Ru, et al.
Publicado: (2021)

Disease burden of chronic hepatitis B and complications in China from 2006 to 2050: an individual-based modeling study
por: Zheng, Yang, et al.
Publicado: (2020)

Modifications of Long Economic Cycles and Prospects for Global Economic Dynamics in 2021–2050
por: Klinov, V. G., et al.
Publicado: (2021)

Pancreatitis, Pancreatic Cancer, and Their Metabolic Sequelae: Projected Burden to 2050
por: Cho, Jaelim, et al.
Publicado: (2020)

Economic and health implications from earlier detection of HIV infection in the United Kingdom
por: Zah, Vladimir, et al.
Publicado: (2016)

Prevalence of hepatitis C infection among the general population and high-risk groups in the EU/EEA: a systematic review update
por: Han, Ru, et al.
Publicado: (2019)

An overview of health technology assessments of gene therapies with the focus on cost-effectiveness models
por: Pochopień, Michał, et al.
Publicado: (2021)

Nasopharyngeal Carcinoma Burden and Its Attributable Risk Factors in China: Estimates and Forecasts from 1990 to 2050
por: Zhang, Ruhao, et al.
Publicado: (2023)

The Economic Burden of Epilepsy in Korea, 2010
por: Jung, Jaehun, et al.
Publicado: (2013)

Age of Retirement and Human Capital in an Aging China, 2015–2050
por: Feng, Qiushi, et al.
Publicado: (2018)

The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
por: Hodgson, J T, et al.
Publicado: (2005)

Estimating the Incidence of Tuberculosis — Shanghai, China, 2025−2050
por: Yu, Shegen, et al.
Publicado: (2020)

Economic impact of new active substance status on EU payers’ budgets: example of dimethyl fumarate (Tecfidera(®)) for multiple sclerosis
por: Toumi, Mondher, et al.
Publicado: (2014)

Economic Impact of a triptan Rx-To-OTC Switch in Six EU Countries
por: Millier, Aurelie, et al.
Publicado: (2013)

Impact of therapy escalation on ambulatory care costs among patients with type 2 diabetes in France
por: Guelfucci, Florent, et al.
Publicado: (2013)

Systematic literature reviews over the years
por: Smela, Beata, et al.
Publicado: (2023)

Regional energy 2050
por: Herrmann, Nicolai
Publicado: (2011)

Desarrollo Industrial 2050/
por: Oropeza García Arturo

Systematic review of utility values used in the pharmacoeconomic evaluations for schizophrenia: implications on cost-effectiveness results
por: Zhou, Junwen, et al.
Publicado: (2019)

Disease burden in Norway in 2050: A forecasting analysis based on the Global Burden of Disease (GBD) Study
por: Knudsen, A K, et al.
Publicado: (2023)

Trends and Challenges for Population Health and Migration — China, 2015−2050
por: Luo, Yanan, et al.
Publicado: (2020)

The quality of life of Spanish patients with Huntington's disease measured with H-QoL-I and EQ-5D
por: Dorey, Julie, et al.
Publicado: (2016)

Economic Burden of Cancer in Korea during 2000-2010
por: Lee, Kwang-Sig, et al.
Publicado: (2015)

Rapid literature review: definition and methodology
por: Smela, Beata, et al.
Publicado: (2023)

A unified physics by 2050?
por: Weinberg, Steven
Publicado: (2003)

Fusion - 2050 perspective (in Polish)
por: Romaniuk, R S
Publicado: (2013)

Projection of the year 2050 burden of diabetes in the US adult population: dynamic modeling of incidence, mortality, and prediabetes prevalence
por: Boyle, James P, et al.
Publicado: (2010)

Trend of myopia through different interventions from 2010 to 2050: Findings from Eastern Chinese student surveillance study
por: Zhang, Xiyan, et al.
Publicado: (2023)

Exploring China stepping into the dawn of chemical pesticide-free agriculture in 2050
por: Wang, Xuejiang, et al.
Publicado: (2022)

Economic evaluation of encorafenib with cetuximab in patients with BRAF V600E-mutant metastatic colorectal cancer in France: a cost-effectiveness analysis using data from the BEACON CRC randomised controlled trial
por: Trouiller, Jean-Baptiste, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fupdlaevb0qpk2pjc4bhbrsp5c